Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma

Cancer

Volumn 88, Issue 2, 2000, Pages 255-261

  Qian, Chao Nan ^a   Zhang, Chang Qing ^a   Guo, Xiang ^a   Hong, Ming Huang ^a   Cao, Su Mei ^a   Mai, Wel Yuan ^a   Min, Hua Qing ^a   Zeng, Yi Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiogenesis; Diagnosis; Metastasis; Nasopharyngeal carcinoma; Serum; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TUMOR VASCULARIZATION;

ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034650190     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000115)88:2<255::AID-CNCR2>3.0.CO;2-N     Document Type: Article

References (42)

1. Ho JHC. An epidemiological and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978;4:183-97.
2. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging and treatment. Semin Oncol 1994;21(3):382-97.
3. Choi PH, Sven MW, Huang DP, Lo KW, Lee JC. Nasopharyngeal carcinoma: genetic changes, Epstein-Barr virus infection, or both. A clinical and molecular study of 36 patients. Cancer 1993;72(10):2873-8.
4. Zhang EP, Lian PG, Lai KL, Chen YF, Cai MD, Zheng XF, et al. Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys 1989;16:301-5.
5. Sham JST, Choy D, Choi PHK. Nasopharyngeal carcinoma: the significant of neck node involvement in relation to the pattern of distant failure. Br J Radiol 1990;63:108-13.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995;1:27-31.
7. Qian CN, Min HQ, Liang XM, Zheng SS, Lin HL. Primary study of neovasculature correlating with metastatic nasopharyngeal carcinoma using computer image analysis. J Cancer Res Clin Oncol 1997;123:645-51.
8. Qian CN, Min HQ, Lin HL, Hong MH, Ye YL. Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol 1998; 112:849-53.
9. Qian CN, Min HQ, Lin HL, Feng GK, Ye YL, Wang LG, et al. Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/HK1. Oncology 1999;57(1):36-41.
10. Dvorak HF, Brier G, Weich HA, Risau W. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability, and angiogenesis. Am J Pathol 1995; 146:1029-39.
11. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Philips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-4.
12. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997;79:233-69.
13. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997;272(11):7151-8.
14. Sugihara T, Wadhwa R, Kaul SC, Mitsui Y. A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF115. J Biol Chem 1998;273(5):3033-8.
15. Watanabe Y, Lee SW, Detmar M, Ajioka I, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997;14:2025-32.
16. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology 1999;53(2):302-7.
17. Maniwa Y, Okada M, Ishii N, Kiyooka K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114(6):1668-75.
18. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998;18(2B): 1251-4.
19. Nomura S, Okamoto T, Matsuo K, Iwase K, Nakanishi T, Suzuki H, et al. Serum and tissue vascular endothelial growth factor levels in hydatidiform mole. Life Sci 1998; 63(20):1793-805.
20. Kitamura M, Toi M, Arai K, Iwasaki Y, Suzuki H, Matsuo K. Concentrations of vascular endothelial growth factor in sera of gastric cancer patients. Oncol Rep 1998;5(6):1419-24.
21. Fujimoto M, Kiyosawa T, Murata S, Matsuo K, Suzuki H, Sone H, et al. Vascular endothelial growth factor in angiosarcoma. Anticancer Res 1998;18(5B):3725-9.
22. Obermair A, Tempfer C, Hefler L, Preyer O, Kaider A, Zeillinger R, et al. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br J Cancer 1998;77(11):1870-4.
23. Chung HC, Rha SY, Ahn JB, Shim KY, Yoo NC, Kim JH, et al. Menstrual state should be considered in determining seropositivity of soluble angiogenic factors in breast cancer. Int J Mol Med 1998;2(4):465-70.
24. Shanmugaratnam K, Sobin LH. World Health Organization international histological classification of tumors: histological typing of tumors of the upper respiratory tract and ear. 2nd ed. Berlin: Springer, 1991.
25. Min HQ, Hong MH, Ma J, Zhang EP, Zheng QX, Zhang J, et al. A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys 1994;30(5):1037-42.
26. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer 1997;79(2):206-13.
27. Orre M, Rogers PA. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer 1999;84(2):101-8.
28. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998;34(9):1439-47.
29. Obermair A, Bancher-Todesca D, Bilgi S, Kaider A, Kohlberger P, Mullauer-Ertl S, et al. Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J Natl Cancer Inst 1997; 89(16):1212-7.
30. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73(7):931-4.
31. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998;79(2):144-6.
32. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90(8):3167-72.
33. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998;78(6):765-70.
34. Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4(5):1279-85.
35. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothellal growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85(1):178-87.
36. Matsamura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of protein and the antitumor agent SMANCS. Cancer Res 1986;46:6387-92.
37. Kamiyama K, Onishi H, Machida Y. Biodisposition characteristics of N-succinyl-chitosan and glycol-chitosan in normal and tumor-bearing mice. Biol Pharmacol Bull 1999; 22(2):179-86.
38. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998;89(3):307-14.
39. Muggia FM. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res 1999;5(1):7-8.
40. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms. Br J Cancer 1997;76(9):1221-7.
41. Yip TTC, Ngan RKC, Lau WH, Poon YF, Joab I, Cochet C, et al. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 trans-activator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 1994;74(9):2414-24.
42. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59(6):1188-91.